While platinum-based chemotherapy remains highly effective, it does pose its own array of barriers, including treatment-induced toxicities, such as secondary malignancies and cardiovascular disease, and platinum-resistant cases associated with KIT and RAS mutations [6,24,36,37]. Here, KIT is linked to cardiovascular disorder.